Home » 近日,AIM ImmunoTech向FDA提交Ampligen作为新冠肺炎后认知功能障碍潜在输注疗法的2期临床研究新药试验前申请

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Subscribe to our Newsletter for new blog posts, tips & new photos.
Let's stay updated!